Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis.

about

Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis.

Item

http://www.wikidata.org/entity/Q52682256

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Efficacy and safety of targeti ...... emic review and meta-analysis.

@en

Efficacy and safety of targeti ...... emic review and meta-analysis.

@nl

type

Item

label

Efficacy and safety of targeti ...... emic review and meta-analysis.

@en

Efficacy and safety of targeti ...... emic review and meta-analysis.

@nl

prefLabel

Efficacy and safety of targeti ...... emic review and meta-analysis.

@en

Efficacy and safety of targeti ...... emic review and meta-analysis.

@nl

P1476

Efficacy and safety of targeti ...... emic review and meta-analysis.

@en

P2093

Dongjie Xiao

http://www.w3.org/2001/XMLSchema#string

Duanrui Liu

http://www.w3.org/2001/XMLSchema#string

Xiaoli Ma

http://www.w3.org/2001/XMLSchema#string

Yanfei Jia

http://www.w3.org/2001/XMLSchema#string

Yunshan Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

Memory Rehabilitation for people with multiple sclerosis

Molecular-targeted first-line therapy for advanced gastric cancer

Apatinib for molecular targeted therapy in tumor

Operating characteristics of a rank correlation test for publication bias

Measuring inconsistency in meta-analyses

Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.

Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.

P304

8120-8132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.23429

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29487720

http://www.w3.org/2001/XMLSchema#string

P932

5814287

http://www.w3.org/2001/XMLSchema#string